Genos Ltd, a Croatia-based company with a strong track record in glycan profiling, is joining GLUCOTYPES as a new partner. This collaboration has been made possible through the successful Hop On Facility grant – HORIZON WIDERA-2023, application, with a total budget of €593,000.
This strategic partnership will strengthen the consortium’s ability to conduct cutting-edge research in glycobiology, particularly in the areas of early glycemic deviations and precision nutrition.
Through this collaboration, Genos will leverage its high-throughput expertise in glycan analysis to support large-scale profiling investigating the role of glycans in early glycemic deviations and the impact of diet on glycans. This partnership will represent a significant step toward translating glycomics research into tangible applications, driving innovation in precision medicine and benefiting both Genos and the broader GLUCOTYPES consortium.
About Genos:
Genos is a leading glycan profiling company specializing in high-throughput glycomics for biomarker discovery, diagnostics, and therapeutic applications.
Irena Trbojević Akmačić, Lead Researcher at Genos Ltd., expressed enthusiasm about the funding success and collaboration, stating: “Thank you once again for giving us a chance to be part of the consortium and for all your support during the application process.“
Welcome to GLUCOTYPES, Genos!
